Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.48 |
| ▸ | PLG | P00747 | 16/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 7/20 | 0.48 |
| ▸ | F2 | P00734 | 6/20 | 0.48 |
| ▸ | F10 | P00742 | 6/20 | 0.48 |
| ▸ | PLAT | P00750 | 4/20 | 0.42 |
| ▸ | HPN | P05981 | 3/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.42 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4451933 | 0.99 | PLAU (0.48) | PLAUPLGST14F2F10 | |
| SCHEMBL2954061 | 0.89 | PLAU (0.52) | PLAUPLGST14F2F10 | |
| Hydrochloric Acid SCHEMBL250043 | 0.88 | PLAU (0.51) | PLAUPLGST14F2F10 | |
| SCHEMBL4619934 | 0.85 | PLAU (0.44) | PLAUPLGST14F2F10 | |
| SCHEMBL4557533 | 0.78 | PLG (0.48) | PLAUPLGST14F2F10 | |
| Hydrochloric Acid SCHEMBL4458403 | 0.77 | PLG (0.47) | PLAUPLGST14F2F10 | |
| SCHEMBL4558058 | 0.76 | PLG (0.43) | PLAUPLGST14F2F10 | |
| SCHEMBL7058121 | 0.74 | PLG (0.43) | PLAUPLGST14F2F10 | |
| SCHEMBL5309785 | 0.72 | PLAU (0.37) | PLAUPLGST14F2F10 | |
| SCHEMBL6129266 | 0.69 | PLAU (0.61) | PLAUPLGST14F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799265-B1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2010-09-08 | — | — | EP | claimed |
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | claimed |
| EP-1534283-B1 | FORMULATION OF LIPOSOMAL DERIVATIVES OF PHENYLALANINE | WILEX AG (DE) | 2005-12-14 | — | — | EP | claimed |
| US-9089532-B2 | Stable dosage form of phenylalanine derivatives | WILEX AG (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-1799265-B1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2010-09-08 | — | — | EP | disclosed |
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7538216-B2 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1799265-A1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | Wilex AG (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006032461-A1 | STABLE DOSING FORM OF PHENYLALANINE DERIVATIVES | WILEX AG (DE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1534283-B1 | FORMULATION OF LIPOSOMAL DERIVATIVES OF PHENYLALANINE | WILEX AG (DE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | WILEX AG (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267127-A1 | Guanidino phenylalanin compounds used as urokinase inhibitors | PLAU, PLAUR, ENPEP | PLAU 1/4885PLG 22/4885ST14 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.